Tacrolimus and sirolimus cause insulin resistance in normal Sprague Dawley rats

Transplantation

Volumn 82, Issue 4, 2006, Pages 466-470

  Larsen, Jennifer L ^a,c   Bennett, Robert G ^a,b   Burkman, Tab ^a   Ramirez, Ana Lisa ^a   Yamamoto, Sakura ^a   Gulizia, James ^a   Radio, Stanley ^a   Hamel, Frederick G ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

Insulin resistance; Sirolimus; Tacrolimus

Indexed keywords

GLUCOSE; INSULIN; RAPAMYCIN; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG INDUCED DISEASE; GLUCOSE BLOOD LEVEL; GRAFT FAILURE; GRAFT SURVIVAL; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; LOW DRUG DOSE; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; ORGAN SIZE; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; RAT; SHORT COURSE THERAPY; SPECIES COMPARISON;

ANIMALS; BLOOD GLUCOSE; IMMUNOSUPPRESSIVE AGENTS; INSULIN; INSULIN RESISTANCE; MALE; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; TACROLIMUS;

EID: 33747890068     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000229384.22217.15     Document Type: Article

References (29)

1. Boudreaux JP, McHugh L, Canafax DM, et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation 1987; 44: 376.
2. First MR, Gerber DA, Hariharan S, Kaufman DB, Shapiro R. Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management. Transplantation 2002; 73: 379.
3. Sato T, Inagaki A, Uchida K, et al. Diabetes mellitus after transplant: relationship to pretransplant glucose metabolism and tacrolimus or cyclosporine A-based therapy. Transplantation 2003; 76: 1320.
4. Marchetti P. New-onset diabetes after liver transplantation: From pathogenesis to management. Liver Transpl 2005; 11: 612.
5. Hirano Y, Fujihara S, Ohara K, et al. Morphological and functional changes of islets of Langerhans in FK506-treated rats. Transplantation 1992; 53: 889.
6. Hirano Y, Mitamura T, Tamura T, et al. Mechanism of FK506-induced glucose intolerance in rats. J Toxiol Sci 1994; 19: 61.
7. Tamura K, Fujimura T, Tsutsumi T, et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. Transplantation 1995; 59: 1606.
8. Drachenberg C, Klassen D, Weir M, et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999; 68: 396.
9. Neto AB, Haapalainen E, Ferreira R, et al. Metabolic and ultrastructural effects of cyclosporin A on pancreatic islets. Transpl Int 1999; 12: 208.
10. Paty BW, Harmon JS, Marsh CL, Robertson RP. Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. Transplantation 2002; 73: 353.
11. Uchizono Y, Iwase M, Nakamura U, et al. Tacrolimus impairment of insulin secretion in isolated rat islets occurs at multiple distal sites in stimulus-secretion coupling. Endocrinology 2004; 145: 2264.
12. van Hooff JP, Christiaans MH, van Duijnhoven EM. Tacrolimus and posttransplant diabetes mellitus in renal transplantation. Transplantation 2005; 79: 1465.
13. Bell E, Cao X, Moibi JA, et al. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 2003; 52: 2731.
14. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230.
15. Drachenberg CB, Papadimitriou JC, Farney A, et al. Pancreas transplantation: the histologic morphology of graft loss and clinical correlations. Transplantation 2001; 71: 1784.
16. Volosov A, Napoli KL, Soldin SJ. Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography-tandem mass-spectrometry. Clin Biochem 2001; 34: 285.
17. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003; 75: SS3.
18. Sulanc E, Lane JT, Puumala SE, et al. New-onset diabetes after kidney transplantation: an application of 2003 international guidelines. Transplantation 2005; 80: 945.
19. Cosio FG, Pesavento TE, Kim S, et al. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002; 62: 1440.
20. Hyder A, Laue C, Schrezenmeir J. Effect of the immunosuppressive regime of Edmonton protocol on the long-term in vitro insulin secretion from islets of two different species and age categories. Toxicol In Vitro 2005; 19: 541.
21. Chueh SC, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 2003; 76: 375.
22. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005; 16: 3128.
23. Smith JL, Hunsicker LG, Yuh WTC, et al. Appearance of Type II diabetes mellitus in Type I diabetic recipients of pancreas allografts. Transplantation 1989; 47: 304.
24. Shapiro AM, Gallant HL, Hao EG, et al. The portal immunosuppressive storm: relevance to islet transplantation? Ther Drug Monit 2005; 27: 35.
25. Lopez-Talavera JC, Garcia-Ocana A, Sipula I, et al. Hepatocyte growth factor gene therapy for pancreatic islets in diabetes: reducing the minimal islet transplant mass required in a glucocorticoid-free rat model of allogeneic portal vein islet transplantation. Endocrinology 2004; 145: 467.
26. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143.
27. de Vries AP, Bakker SJ, van Son WJ, et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 2004; 4: 1675.
28. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178.
29. van Hooff JP, Christiaans MH, van Duijnhoven EM. Evaluating mechanisms of post-transplant diabetes mellitus. Nephrol Dial Transplant 2004; 19 Suppl 6: vi8.